Genotypic Antimicrobial Resistance Testing in Stewardship

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

• Genotypic antimicrobial resistance testing detects resistance genes or mutations directly from clinical samples or cultured isolates, enabling earlier therapy optimization than phenotype-based susceptibility testing.
• Use genotypic results to guide initial antibiotic selection while confirmatory phenotypic susceptibility testing is pending, but never use genotypic data alone for final therapy decisions.
• A key limitation is that genotypic tests detect known resistance mechanisms only, so negative results do not rule out resistance mediated by novel or uncharacterized pathways.

At a Glance

Understanding Genotypic Antimicrobial Resistance Testing

Genotypic antimicrobial resistance testing identifies the genetic basis of resistance in bacteria by detecting specific resistance genes, mutations, or genetic elements that confer reduced susceptibility to antibiotics. This approach contrasts with phenotypic testing, which measures the observable growth response of a microorganism to an antibiotic under standardized conditions. The Clinical and Laboratory Standards Institute provides the standards-based framework for antimicrobial susceptibility testing that laboratories use to generate clinically actionable results, and genotypic methods increasingly complement these phenotypic approaches in clinical microbiology workflows.

The global public health context for genotypic resistance testing is defined by the World Health Organization, which describes antimicrobial resistance as a process by which bacteria change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness, and death. Genotypic testing serves as one of the tools that laboratories and stewardship teams can use to detect resistance mechanisms earlier and more precisely than traditional culture-based methods alone.

Core Principles of Genotypic Resistance Detection

Genotypic resistance testing operates on the principle that specific genetic determinants correlate with reduced antibiotic susceptibility. These determinants include acquired resistance genes carried on mobile genetic elements such as plasmids and transposons, as well as chromosomal mutations that alter drug targets, reduce drug uptake, or increase drug efflux. The presence of a resistance gene does not always guarantee phenotypic resistance, because gene expression, promoter strength, and copy number can influence the final resistance phenotype.

Conversely, phenotypic resistance can occur without detection of a known resistance gene, because the resistance mechanism may be novel, may involve complex interactions among multiple genes, or may result from mutations that are not included in the test panel. This discordance between genotype and phenotype is a central limitation that clinicians and laboratory professionals must understand when interpreting genotypic resistance results.

The American Society for Microbiology provides professional education and laboratory practice context that emphasizes the importance of integrating genotypic and phenotypic data in clinical microbiology. The ASM framework supports the view that genotypic resistance testing is most valuable when used as a complementary tool alongside traditional susceptibility testing, not as a replacement for it.

How Genotypic Testing Differs from Phenotypic Testing

Phenotypic susceptibility testing measures the observable response of a microorganism to an antibiotic. The minimum inhibitory concentration, or MIC, is the lowest concentration of an antibiotic that prevents visible growth of a microorganism under standardized conditions. Phenotypic testing provides a direct measure of susceptibility or resistance, but it requires viable culture growth and typically takes 16 to 72 hours after the organism has been isolated.

Genotypic testing detects the genetic potential for resistance without requiring the organism to express that resistance during the test. This means genotypic results can be available much earlier in the diagnostic workflow, often directly from a clinical sample or from a positive blood culture bottle. The tradeoff is that genotypic testing provides an indirect measure of resistance, and the clinical meaning of a detected gene depends on the strength of the evidence linking that gene to phenotypic resistance.

The CLSI standards for antimicrobial susceptibility testing provide the interpretive framework that laboratories use to translate MIC values into susceptibility categories. Genotypic results do not have the same standardized interpretive framework, and laboratories must validate their genotypic methods against phenotypic reference methods to ensure clinical reliability.

The Stewardship Problem That Genotypic Testing Addresses

Antimicrobial stewardship programs aim to optimize antibiotic use to improve patient outcomes, reduce adverse effects, and limit the emergence of resistance. The WHO identifies antimicrobial stewardship as a core component of the global response to antimicrobial resistance, emphasizing the need to preserve the effectiveness of existing antibiotics through responsible use.

The clinical problem that genotypic resistance testing addresses is the delay between sample collection and actionable susceptibility information. In serious infections such as sepsis, the time between the initial blood culture and the availability of phenotypic susceptibility results can be 48 to 72 hours or longer. During this period, patients often receive broad-spectrum empiric antibiotics that may be unnecessarily broad, potentially toxic, or ineffective against the specific pathogen.

Genotypic resistance testing can reduce this uncertainty by providing early information about the presence of key resistance mechanisms. For example, detection of a carbapenemase gene in a Gram-negative bloodstream isolate can alert the clinical team that the organism is likely resistant to carbapenems, prompting earlier use of alternative agents. This early information can improve the precision of antibiotic therapy and support the stewardship goal of using the narrowest effective agent.

Rapid Diagnostic Tests for Genotypic Resistance

Rapid molecular diagnostic tests have transformed the clinical microbiology laboratory by enabling detection of resistance genes directly from clinical samples or from positive blood culture broths within hours. These tests use polymerase chain reaction, or PCR, and related amplification technologies to detect specific DNA sequences that correspond to resistance genes.

PCR-Based Panels

Multiplex PCR panels are designed to detect a defined set of pathogens and resistance genes simultaneously. These panels are particularly useful for bloodstream infections, where rapid identification of the causative organism and its resistance mechanisms can guide therapy within hours of a positive blood culture.

The panels typically include primers for common resistance genes such as mecA for methicillin resistance in staphylococci, vanA and vanB for vancomycin resistance in enterococci, and genes encoding carbapenemases such as KPC, NDM, VIM, IMP, and OXA-48 in Gram-negative bacilli. The presence of these genes provides strong evidence that the organism is resistant to the corresponding antibiotic class.

The clinical utility of these panels depends on the prevalence of the targeted resistance genes in the local patient population. A panel that includes genes that are rare in a particular hospital may have limited positive predictive value, while a panel that misses a locally common resistance mechanism may produce false reassurance. Stewardship teams should review local epidemiology when selecting and interpreting rapid molecular panels.

Whole Genome Sequencing

Whole genome sequencing provides the most comprehensive genotypic resistance information because it sequences the entire genome of the organism instead of targeting a predefined set of genes. WGS can identify known resistance genes, detect mutations in chromosomal genes that confer resistance, and reveal the genetic context of resistance determinants, such as whether they are carried on mobile genetic elements.

The workflow for WGS involves DNA extraction, library preparation, sequencing, and bioinformatics analysis. The bioinformatics step is critical because it involves comparing the sequenced genome against curated databases of resistance genes and mutations. The quality of the resistance prediction depends on the completeness of the reference database and the accuracy of the bioinformatics pipeline.

WGS is more expensive and time-consuming than PCR-based panels, and it requires specialized expertise in bioinformatics. However, it provides the most complete picture of the resistance potential of an organism and is particularly valuable for outbreak investigations, surveillance, and understanding the epidemiology of resistance in a healthcare setting.

The American Type Culture Collection provides authenticated biological materials that are essential for quality control in genotypic testing. Reference strains with known resistance genotypes are used to validate test performance, ensure reproducibility, and maintain quality standards in clinical and research laboratories.

Incorporating Genotypic Data into Stewardship Algorithms

The value of genotypic resistance testing is realized only when the results are integrated into clinical decision-making in a structured and reliable way. Stewardship algorithms provide a framework for translating genotypic results into actionable therapy recommendations.

Building a Stewardship Algorithm

A stewardship algorithm for genotypic resistance testing should define the clinical scenarios in which genotypic testing is appropriate, the specific tests to be used, the interpretation of results, and the actions to be taken based on the results. The algorithm should be developed by a multidisciplinary team that includes stewardship pharmacists, infectious disease physicians, clinical microbiologists, and infection prevention personnel.

The algorithm should specify the patient populations that will benefit most from rapid genotypic testing, such as patients with sepsis, patients in intensive care units, and patients with infections caused by organisms that are known to have high rates of resistance. The algorithm should also define the workflow for ordering genotypic tests, the time frame for result reporting, and the mechanism for communicating results to the clinical team.

Interpreting Genotypic Results in Clinical Context

The interpretation of genotypic resistance results requires careful consideration of the clinical context. A positive result for a resistance gene indicates that the organism has the genetic potential for resistance, but the clinical significance depends on the specific gene, the organism, and the antibiotic being considered.

For example, detection of the mecA gene in a Staphylococcus aureus isolate indicates that the organism is likely resistant to all beta-lactam antibiotics, including methicillin, oxacillin, and cephalosporins. This result has direct therapeutic implications because it rules out the use of beta-lactam antibiotics and supports the use of alternative agents.

A negative result for a resistance gene does not rule out resistance. The organism may carry a resistance gene that is not included in the test panel, or it may have a resistance mechanism that is not genetically detectable. The stewardship algorithm should specify that negative genotypic results should be confirmed by phenotypic testing before the antibiotic is used.

The Role of Phenotypic Confirmation

Phenotypic susceptibility testing remains the reference standard for determining the clinical susceptibility of an organism to an antibiotic. Genotypic results should be used to guide initial therapy, but they should not replace phenotypic testing for final therapy decisions.

The stewardship algorithm should specify that phenotypic susceptibility testing is always performed in parallel with genotypic testing when possible. The genotypic result can be used to select the most appropriate empiric therapy, and the phenotypic result is used to confirm the therapy and to detect resistance mechanisms that were not identified by the genotypic test.

The CLSI standards for antimicrobial susceptibility testing provide the framework for phenotypic testing and the interpretive criteria that laboratories use to report susceptibility categories. These standards are essential for ensuring that phenotypic results are reliable and clinically meaningful.

Practical Implementation Steps

Implementing genotypic resistance testing in a clinical laboratory requires careful planning and coordination across multiple disciplines. The following steps provide a practical framework for implementation.

Step 1: Assess Local Epidemiology and Clinical Needs

The first step is to assess the local epidemiology of antimicrobial resistance and the clinical needs of the patient population. This assessment should include a review of the most common resistant organisms in the hospital, the resistance mechanisms that are most clinically relevant, and the current time to result for phenotypic susceptibility testing.

The assessment should also consider the clinical scenarios in which genotypic testing would have the greatest impact. For example, a hospital with a high rate of carbapenem-resistant Enterobacterales infections may benefit from a rapid panel that detects carbapenemase genes, while a hospital with a low rate of these infections may not justify the cost.

Step 2: Select the Appropriate Genotypic Test

The selection of a genotypic test should be based on the clinical needs identified in the assessment. The test should detect the resistance genes that are most relevant to the local patient population, and it should have a turnaround time that is compatible with the clinical workflow.

The test should be validated in the laboratory before clinical use. Validation should include testing a panel of well-characterized organisms with known resistance genotypes, including both positive and negative controls. The validation should also include a comparison of genotypic results with phenotypic susceptibility results to ensure that the test is accurate.

Step 3: Develop the Stewardship Algorithm

The stewardship algorithm should be developed by the multidisciplinary team and should specify the clinical scenarios in which genotypic testing is used, the interpretation of results, and the actions to be taken. The algorithm should be reviewed and approved by the hospital pharmacy and therapeutics committee or the equivalent governance body.

The algorithm should be integrated into the electronic health record where possible, so that genotypic results are automatically flagged for the stewardship team and the clinical team. The algorithm should also include a mechanism for the stewardship team to review genotypic results and provide recommendations to the clinical team.

Step 4: Train the Clinical Team

The clinical team must be trained to interpret genotypic resistance results and to use them appropriately in clinical decision-making. The training should cover the principles of genotypic resistance testing, the interpretation of results, and the limitations of the testing.

The training should also cover the importance of phenotypic confirmation and the need to consider the clinical context when interpreting genotypic results. The training should be provided to physicians, pharmacists, nurses, and other clinical staff who are involved in the care of patients with infections.

Step 5: Monitor and Evaluate the Program

The genotypic resistance testing program should be monitored and evaluated on an ongoing basis. The monitoring should include the turnaround time for genotypic results, the accuracy of the results, and the impact of the results on clinical outcomes.

The evaluation should include a review of the clinical decisions that were made based on genotypic results, the appropriateness of the antibiotic therapy, and the patient outcomes. The evaluation should also include a review of the cost-effectiveness of the program and the impact on the use of broad-spectrum antibiotics.

Records and Measurements

Accurate records and measurements are essential for the effective use of genotypic resistance testing in stewardship programs. The records should document the genotypic results, the phenotypic results, the clinical decisions, and the patient outcomes.

Key Records to Maintain

The laboratory should maintain records of all genotypic tests performed, including the test type, the sample type, the date and time of the test, the result, and the interpretation. The records should also include the quality control results for each test run, including the positive and negative controls.

The stewardship team should maintain records of the clinical decisions that were made based on genotypic results, including the antibiotic therapy that was prescribed, the time to the first dose of the appropriate antibiotic, and the time to the discontinuation of the empiric therapy.

The records should also include the patient outcomes, including the length of stay, the mortality, and the rate of adverse events. These records are used to evaluate the impact of the genotypic testing program and to identify areas for improvement.

Measurements to Track

The key measurements for a genotypic resistance testing program include the turnaround time for genotypic results, the time to the first dose of the appropriate antibiotic, the time to the discontinuation of the empiric therapy, and the rate of clinical cure.

The turnaround time for genotypic results should be measured from the time the sample is received in the laboratory to the time the result is reported to the clinical team. The time to the first dose of the appropriate antibiotic should be measured from the time the sample is collected to the time the patient receives the first dose of the antibiotic that is appropriate for the resistance genotype.

The rate of clinical cure should be measured as the proportion of patients who have a resolution of the infection after the genotypic-guided therapy. The rate of adverse events should be measured as the proportion of patients who experience an adverse event related to the antibiotic therapy.

Common Failure Patterns

The implementation of genotypic resistance testing can fail in several ways, and understanding these failure patterns is essential for the successful use of the testing.

Overreliance on Genotypic Results

The most common failure pattern is the overreliance on genotypic results without phenotypic confirmation. A negative genotypic result can lead to the use of an antibiotic that is ineffective, while a positive genotypic result can lead to the use of an antibiotic that is unnecessarily broad.

The stewardship team must emphasize that genotypic results are a supplement to phenotypic testing, not a replacement. The clinical team must be trained to wait for the phenotypic results before making the final therapy decision.

Incomplete Test Panels

A second failure pattern is the use of a genotypic test panel that does not include the resistance genes that are most relevant to the local patient population. This can lead to false-negative results and the use of ineffective antibiotics.

The stewardship team must evaluate the local epidemiology of resistance and select a test panel that includes the most relevant resistance genes. The panel should be reviewed on a regular basis to ensure that it remains relevant as the local epidemiology changes.

Poor Communication of Results

A third failure pattern is the poor communication of genotypic results to the clinical team. If the results are not reported in a timely manner, or if the results are not interpreted in the clinical context, the value of the testing is lost.

The stewardship team must establish a clear communication pathway for genotypic results. The results should be reported to the clinical team as soon as they are available, and the stewardship team should provide a clinical interpretation of the results.

Lack of Clinical Integration

A fourth failure pattern is the lack of integration of genotypic results into the clinical workflow. If the results are not integrated into the electronic health record, or if the stewardship team does not review the results, the testing will not have an impact on patient outcomes.

The stewardship team must ensure that the genotypic results are integrated into the clinical workflow and that the results are reviewed by the stewardship team on a regular basis.

Biosafety and Laboratory Considerations

The genotypic resistance testing involves the handling of clinical samples and bacterial isolates, and the laboratory must follow the appropriate biosafety practices to protect laboratory personnel and the environment.

Risk Assessment and Containment

The laboratory must conduct a risk assessment for the procedures used in genotypic resistance testing, including the handling of clinical samples, the culture of bacterial isolates, and the extraction of nucleic acids. The risk assessment should consider the potential for exposure to infectious agents and the appropriate containment measures.

The CDC and NIH provide the Biosafety in Microbiological and Biomedical Laboratories guidance, which describes the principles of biosafety, the risk assessment, and the containment levels for laboratory work. The laboratory must follow the biosafety practices that are appropriate for the risk level of the work being performed.

Decontamination and Waste Management

The laboratory must have procedures for the decontamination of work surfaces, equipment, and waste. The decontamination procedures should be effective against the microorganisms that are being handled, and the waste should be disposed of in accordance with the applicable regulations.

The laboratory must also have procedures for the management of spills and the decontamination of the laboratory in the event of a spill. The procedures should be documented and the laboratory personnel must be trained on the procedures.

Quality Control and Authenticated Materials

The quality control for genotypic resistance testing should include the use of authenticated biological materials, such as the reference strains from the American Type Culture Collection. These strains have known resistance genotypes and are used to validate the performance of the test and to monitor the quality of the testing.

The quality control should include the positive and negative controls for each test, and the results of the quality control should be documented. The quality control should be performed on a regular basis, and the results should be reviewed to ensure that the test is performing correctly.

Professional Escalation Criteria

The stewardship team should have clear criteria for escalating the clinical concerns that are identified through genotypic resistance testing. The escalation criteria should be defined in the stewardship algorithm and should be communicated to the clinical team.

Escalation for the Detection of a Resistance Gene

When a genotypic test detects a resistance gene that is associated with a high level of resistance to a clinically important antibiotic, the stewardship team should be notified immediately. The stewardship team should review the clinical case and provide recommendations for the alternative antibiotic therapy.

The escalation should include the notification of the infectious disease physician and the infection control team, because the detection of a resistance gene may indicate the presence of a resistant organism that requires infection control measures.

Escalation for the Discordance between Genotypic and Phenotypic Results

When the genotypic result is discordant with the phenotypic result, the stewardship team should be notified to review the case. The discordance may be due to a technical error, a novel resistance mechanism, or a problem with the interpretation of the results.

The stewardship team should review the clinical case and determine the appropriate course of action. The discordance should be documented and the laboratory should be notified to investigate the cause of the discordance.

Escalation for the Clinical Deterioration

When the clinical condition of the patient deteriorates despite the genotypic-guided therapy, the stewardship team should be notified to review the case. The deterioration may be due to the resistance that was not detected by the genotypic test, or it may be due to the other clinical factors.

The stewardship team should review the clinical case and the laboratory results, and the clinical team should consider the alternative therapy. The escalation should be documented and the outcome should be reviewed.

The Role of Genotypic Testing in Surveillance

Genotypic resistance testing is also a tool for individual patient care but also a tool for surveillance of antimicrobial resistance at the local, national, and global levels. The WHO describes the importance of surveillance in the global response to antimicrobial resistance, and genotypic testing provides a powerful tool for understanding the epidemiology of resistance.

Local Surveillance

The local surveillance of genotypic resistance can help the hospital to understand the resistance patterns in the patient population and to identify the emerging resistance threats. The surveillance data can be used to inform the empiric antibiotic guidelines and to guide the selection of the genotypic test panels.

The surveillance data should be reviewed on a regular basis, and the findings should be communicated to the clinical team and the infection control team. The surveillance data can also be used to evaluate the impact of the stewardship program on the resistance patterns.

National and Global Surveillance

The genotypic resistance data can be shared with the national and global surveillance systems to contribute to the understanding of the global epidemiology of resistance. The WHO coordinates the global surveillance of antimicrobial resistance, and the data from the genotypic testing can be used to inform the global response.

The sharing of the genotypic data should be done in a way that protects the privacy of the patients and the confidentiality of the data. The data should be shared in a standardized format to ensure that the data can be compared across the different settings.

The Future of Genotypic Resistance Testing

The field of genotypic resistance testing is evolving rapidly, and the future of the testing will be shaped by the advances in the sequencing technology, the bioinformatics, and the clinical integration.

Advances in Sequencing Technology

The advances in the sequencing technology are making the whole genome sequencing faster, cheaper, and more accessible. The development of the portable sequencing devices and the automated bioinformatics pipelines is making it possible to use the WGS in the clinical laboratory setting.

The advances in the sequencing technology are also making it possible to sequence the clinical samples directly, without the need for the culture. This approach, known as the metagenomic sequencing, has the potential to provide the comprehensive resistance information from the clinical sample within a single day.

Advances in Bioinformatics

The advances in the bioinformatics are making it possible to interpret the genotypic resistance data more accurately and more quickly. The development of the curated resistance databases and the machine learning algorithms is improving the accuracy of the resistance prediction.

The bioinformatics tools are also making it possible to integrate the genotypic data with the clinical data to provide the clinical decision support. The integration of the genotypic data into the electronic health record is making it possible to provide the real-time clinical decision support to the clinical team.

The Integration of Genotypic and Phenotypic Data

The future of the genotypic resistance testing will be the integration of the genotypic and phenotypic data to provide a comprehensive picture of the resistance of the organism. The integration of the data will make it possible to predict the clinical susceptibility of the organism to the antibiotics with the greater accuracy.

The integration of the data will also make it possible to identify the novel resistance mechanisms and to understand the complex interactions between the resistance genes and the clinical outcomes. The integration of the data will be essential for the development of the personalized antibiotic therapy.

A Practical Decision Framework for Genotypic Result Discordance

Genotypic resistance testing produces results that occasionally conflict with phenotypic susceptibility findings, and stewardship teams need a structured method for resolving these discrepancies. A discordance occurs when a genotypic test detects a resistance gene but the phenotypic test reports susceptibility, or when a genotypic test is negative but the phenotypic test demonstrates resistance. These situations create clinical uncertainty because the optimal antibiotic choice depends on which result reflects the true resistance phenotype. A practical decision framework helps the stewardship pharmacist and infectious disease physician work through discordant results systematically instead of relying on intuition or anecdotal experience.

Step 1: Classify the Discordance Type

The first action is to classify the discordance into one of three categories. A genotype-positive phenotype-negative discordance means the resistance gene was detected but the organism tested susceptible by phenotypic methods. A genotype-negative phenotype-positive discordance means no resistance gene was detected but the organism demonstrated resistance phenotypically. A third category involves indeterminate results where the genotypic test produced an invalid or uninterpretable signal that requires repeat testing.

Each discordance type has distinct implications. Genotype-positive phenotype-negative results may reflect gene expression differences, promoter mutations, or the presence of a gene that is not phenotypically expressed under standard testing conditions. Genotype-negative phenotype-positive results suggest a resistance mechanism that is not included in the test panel, a novel mechanism, or a technical failure in the genotypic assay. The classification step determines which investigation pathway the stewardship team should follow.

Step 2: Verify Specimen and Test Integrity

Before interpreting any discordance, the stewardship team should verify that the genotypic and phenotypic tests were performed on the same isolate. Mixed cultures, contaminated specimens, or labeling errors can produce apparent discordance when the genotypic and phenotypic tests actually evaluated different organisms. The laboratory should confirm the isolate identity using standard identification methods and review the specimen handling records.

The team should also review the quality control records for both tests. The Clinical and Laboratory Standards Institute provides the standards-based framework for antimicrobial susceptibility testing, and the laboratory should confirm that the phenotypic test was performed according to the validated protocol with appropriate control strains. The American Type Culture Collection provides authenticated biological materials that serve as reference strains for quality control, and the laboratory should verify that the control results were within the acceptable range for the test run.

Step 3: Assess the Clinical Significance

The clinical significance of a discordance depends on the specific organism, the antibiotic class, and the patient context. A discordance involving a carbapenemase gene in a critically ill patient with a bloodstream infection carries more weight than a discordance involving a less clinically consequential resistance determinant. The stewardship team should evaluate the strength of the evidence linking the detected gene to phenotypic resistance, the local epidemiology of resistance, and the availability of alternative antibiotic options.

The WHO describes antimicrobial resistance as a process by which bacteria change over time and no longer respond to medicines, and the clinical significance of a discordance should be interpreted in this context. If the detected gene is known to confer resistance to a class of antibiotics that is essential for treating the infection, the stewardship team should err toward the genotypic result and select an alternative agent while the discrepancy is investigated.

Step 4: Apply the Default Action Rules

The framework should include default action rules that guide the initial clinical response. For a genotype-positive phenotype-negative discordance involving a gene with strong evidence of clinical resistance, the default action is to treat the organism as resistant to the corresponding antibiotic class until the discordance is resolved. This conservative approach protects the patient from potential treatment failure.

For a genotype-negative phenotype-positive discordance, the default action is to treat the organism as resistant based on the phenotypic result. The phenotypic test provides a direct measure of the organism response to the antibiotic, and the absence of a detected gene does not rule out resistance. The stewardship team should consider whether the genotypic test panel was appropriate for the organism and whether additional testing is needed.

Step 5: Initiate the Investigation and Follow-Up

The stewardship team should initiate a laboratory investigation for every discordance that affects clinical decision-making. The investigation should include a review of the genotypic test panel to determine whether the resistance mechanism is one that the panel is designed to detect, a review of the phenotypic testing conditions, and a repeat of both tests if necessary.

The investigation should also include a review of the local epidemiology of resistance. If the discordance involves a resistance mechanism that is emerging in the local patient population, the stewardship team should consider whether the genotypic test panel needs to be updated. The American Society for Microbiology provides professional education and laboratory practice context that supports the continuous evaluation of laboratory methods and the integration of new evidence into clinical practice.

Records and Measurements for Discordance Management

The stewardship team should maintain a discordance log that records the date, the organism, the genotypic result, the phenotypic result, the clinical decision, and the outcome of the investigation. The log should be reviewed on a regular basis to identify patterns in discordance that may indicate a problem with the test panel or the interpretation criteria.

The key measurements for the discordance framework include the discordance rate, calculated as the number of discordant results divided by the total number of paired genotypic and phenotypic tests, and the time to resolution, measured from the identification of the discordance to the final clinical decision. The discordance rate should be tracked over time to identify changes that may indicate a shift in the local resistance epidemiology or a change in the test performance.

Common Failure Patterns in Discordance Management

A common failure pattern is the immediate dismissal of the genotypic result when the phenotypic result is susceptible. This approach can lead to treatment failure if the gene is expressed under clinical conditions even though it is not expressed under standard phenotypic testing conditions. The stewardship team should resist the temptation to ignore the genotypic result and should follow the default resolution strategy.

Another failure pattern is the failure to investigate the discordance in a timely manner. If the discordance is not investigated, the laboratory cannot determine whether the test panel needs to be updated or whether a technical error occurred. The stewardship team should establish a time frame for the investigation and should document the outcome.

A third failure pattern is the failure to communicate the discordance to the clinical team. The clinical team may not be aware of the discordance if the results are reported separately, and the stewardship team should ensure that the discordance is communicated with a clear recommendation for the clinical action.

Professional Escalation Criteria for Discordance

The stewardship team should escalate the discordance to the laboratory director or the infectious disease physician when the discordance involves a resistance gene that is associated with a high level of resistance to a clinically important antibiotic, when the discordance is repeated for the same organism and antibiotic, or when the discordance cannot be resolved through the standard investigation. The escalation should include a summary of the clinical case, the genotypic and phenotypic results, and the investigation findings.

The escalation should also occur when the discordance suggests the presence of a novel resistance mechanism that is not included in the test panel. The laboratory should be notified to consider the additional testing, and the stewardship team should consider the public health implications of the novel resistance mechanism. The WHO provides the global context for the surveillance of antimicrobial resistance, and the stewardship team should report the novel resistance mechanism to the appropriate surveillance system if the mechanism is confirmed.

Frequently Asked Questions

What is the difference between genotypic and phenotypic antimicrobial resistance testing?

Genotypic testing detects the genetic determinants of resistance, such as resistance genes or mutations, while phenotypic testing measures the observable growth response of the organism to an antibiotic. Genotypic testing can be faster and can be performed directly on clinical samples, but it provides a predictive measure of resistance. Phenotypic testing provides a direct measure of susceptibility but requires culture growth and takes longer.

How can genotypic resistance results be used to optimize antibiotic therapy?

Genotypic resistance results can be used to select the initial antibiotic therapy when the phenotypic results are not yet available. A positive result for a resistance gene can rule out the use of the corresponding antibiotic class and guide the selection of an alternative agent. The genotypic results should always be confirmed by phenotypic testing before the final therapy decision.

What are the limitations of genotypic antimicrobial resistance testing?

Genotypic testing detects only the resistance genes that are included in the test panel, so a negative result does not rule out resistance. The presence of a resistance gene does not always guarantee the resistance phenotype, because the gene expression and the regulatory context can influence the resistance. Genotypic results must be interpreted in the clinical context and confirmed by the phenotypic testing.

When should genotypic resistance testing be used in a stewardship program?

Genotypic resistance testing should be used in clinical scenarios where the early detection of resistance can improve the patient outcomes, such as in patients with severe sepsis or in patients with infections at high risk of resistance. The testing should be used as a complement to the phenotypic testing, and the results should be integrated into the stewardship algorithm.

What is the role of the whole genome sequencing in genotypic resistance testing?

Whole genome sequencing provides a comprehensive analysis of the resistance potential of an organism by sequencing the entire genome. It can detect the known resistance genes, the novel mutations, and the genetic context of the resistance. WGS is more expensive and more complex than the PCR-based tests, and it requires the bioinformatics expertise.

How should genotypic resistance results be reported to the clinical team?

The genotypic resistance results should be reported to the clinical team as soon as they are available, and the results should be interpreted in the clinical context. The stewardship team should provide the clinical interpretation of the results and the recommendations for the antibiotic therapy. The results should be integrated into the electronic health record to ensure that the clinical team has access to the results.

What quality controls are needed for genotypic resistance testing?

The quality controls for genotypic resistance testing should include the use of the authenticated biological materials with the known resistance genotypes, the positive and negative controls for each test, and the regular review of the quality control results. The quality controls should be documented and the laboratory should follow the biosafety guidance for the handling of the samples.

How does genotypic resistance testing contribute to antimicrobial resistance surveillance?

Genotypic resistance testing provides the data on the resistance mechanisms that are present in the bacterial population, which can be used for the surveillance of the antimicrobial resistance at the local, national, and global levels. The surveillance data can be used to inform the antibiotic stewardship guidelines and to identify the emerging resistance threats.

Using the Evidence

Related Bacteriology Guides

• Bacterial Infections in Poultry: Clinical Manifestations, Diagnosis, and Antimicrobial Therapy
• Trueperella pyogenes: Taxonomy, Virulence, Pathogenesis, Antimicrobial Resistance, and Molecular Epidemiology
• Lyme Disease in Dogs: Borrelia burgdorferi Serological and Molecular Testing in Endemic Regions
• Biological Foundation Models for Antimicrobial Peptide Discovery in Veterinary Pathogens
• Duck Viral Enteritis: Clinical Disease and Management

References and Further Reading

• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• Microbiology Resources. American Society for Microbiology.
• Antimicrobial Resistance. World Health Organization.
• Bacteriological Analytical Manual. U.S. Food and Drug Administration.
• Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
• Culture Collections. American Type Culture Collection.
• NCBI Pathogen Detection. National Center for Biotechnology Information.
• Laboratory detection of carbapenemases among Gram-negative organisms.. Clinical microbiology reviews, 2024.
• Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists.. Pharmacotherapy, 2023.
• Bloodstream infections in critically ill patients: an expert statement.. Intensive care medicine, 2020.
• Antibiotic susceptibility testing for therapy and antimicrobial resistance surveillance: genotype beats phenotype?. Future microbiology, 2022.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.